Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samalizumab in Advanced Solid Tumors
NCT02987504Phase 1Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of samalizumab in solid tumor (advanced stage), sponsored by Alexion Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Plasma Concentration at 21 days and 1 more. Started Nov 2016; status: terminated.
02
Drugs
samalizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02987504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987504.